Sphera Funds Management LTD. raised its stake in Aerpio Pharmaceuticals Inc (OTCMKTS:ARPO) by 2.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,131,819 shares of the company’s stock after buying an additional 28,265 shares during the quarter. Sphera Funds Management LTD. owned about 2.79% of Aerpio Pharmaceuticals worth $3,497,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Orbimed Advisors LLC acquired a new stake in shares of Aerpio Pharmaceuticals during the second quarter worth about $21,555,000. Millennium Management LLC acquired a new stake in shares of Aerpio Pharmaceuticals during the second quarter worth about $934,000. FMR LLC acquired a new stake in shares of Aerpio Pharmaceuticals during the second quarter worth about $3,648,000. Finally, Nexthera Capital LP acquired a new stake in shares of Aerpio Pharmaceuticals during the second quarter worth about $1,240,000. 0.37% of the stock is currently owned by institutional investors.
Shares of Aerpio Pharmaceuticals stock opened at $2.08 on Friday. Aerpio Pharmaceuticals Inc has a 52 week low of $1.75 and a 52 week high of $5.50.
Several analysts have recently issued reports on the stock. Guggenheim assumed coverage on shares of Aerpio Pharmaceuticals in a research report on Wednesday, September 19th. They set a “buy” rating and a $10.00 price target on the stock. Zacks Investment Research raised shares of Aerpio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 price target on the stock in a research report on Monday, August 20th. Finally, HC Wainwright set a $9.00 price target on shares of Aerpio Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 15th.
In other news, CEO Stephen J. Hoffman purchased 31,967 shares of the company’s stock in a transaction dated Monday, November 12th. The stock was acquired at an average price of $2.01 per share, for a total transaction of $64,253.67. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Muneer A. Satter purchased 60,000 shares of the company’s stock in a transaction dated Friday, November 30th. The stock was purchased at an average price of $1.98 per share, with a total value of $118,800.00. The disclosure for this purchase can be found here. Insiders bought 151,967 shares of company stock valued at $308,454 over the last three months. Corporate insiders own 38.60% of the company’s stock.
WARNING: This report was reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.tickerreport.com/banking-finance/4001195/aerpio-pharmaceuticals-inc-arpo-holdings-lifted-by-sphera-funds-management-ltd.html.
Aerpio Pharmaceuticals Profile
Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema.
See Also: Bull Market
Receive News & Ratings for Aerpio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerpio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.